FDA's New Rules: Checking if Pills Play Nice with Pregnancies
Published Date: 5/11/2026
Notice
Summary
The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
New Method Guidance: Registries & Rare Exposures
The final guidance updates methods for postapproval pregnancy safety work by clarifying the pregnancy registry section (including a new statistical methods subsection), broadening complementary study methods, expanding discussion on collecting data when rare exposures are expected, and updating terminology to include descriptive pregnancy safety studies. These methodological updates affect how sponsors and investigators design and document postapproval pregnancy safety investigations.
Final FDA Guidance for Pregnancy Safety Studies
On May 11, 2026 the FDA published a final guidance called "Postapproval Pregnancy Safety Studies" that gives recommendations to drug sponsors and investigators on how to design studies that assess safety outcomes in pregnant women after a drug or biologic is approved. The guidance finalizes a draft originally issued on May 9, 2019 and is available to industry and investigators for immediate use.
Guidance Is Non-Binding and Deregulatory
FDA states the guidance reflects its current thinking but is not binding; sponsors may use alternative approaches if they meet statute and regulation requirements. FDA also assessed this action as an Executive Order 14192 deregulatory action and the guidance contains no new collections of information under the Paperwork Reduction Act.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-09267 — Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers create medicines that treat, prevent, or stop Clostridioides difficile infections (CDI) from coming back. This update affects companies working on CDI drugs and aims to speed up safe, effective treatments reaching patients. The guidance is official as of May 11, 2026, and could save time and money by clarifying what’s needed for drug approval.
Next: 2026-09269 — Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability
The FDA just released final guidance to help drug makers create new medicines to treat lung tuberculosis (TB). This update affects companies developing TB drugs by clarifying how to test and prove their treatments work safely and effectively. The guidance is official as of May 11, 2026, aiming to speed up better TB treatments without extra costs for the public.